- Home
- HUMA vs IPHA Comparison
HUMA vs IPHA Comparison
Compare HUMA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | IPHA |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.6M | 160.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HUMA | IPHA |
|---|---|---|
| Price | $1.20 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $10.00 | $5.00 |
| AVG Volume (30 Days) | ★ 5.9M | 16.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.31 |
| Revenue Next Year | $731.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $1.57 |
| 52 Week High | $3.35 | $2.63 |
Technical Indicators
Market Signals| Indicator | HUMA | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 44.30 |
| Support Level | $0.92 | $1.60 |
| Resistance Level | $1.26 | $1.86 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 70.45 | 27.04 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.